Q3 EPS Estimate for Lineage Cell Therapeutics Cut by Analyst

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – Stock analysts at HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for Lineage Cell Therapeutics in a research report issued on Friday, August 7th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($0.03) per share for the quarter, down from their previous forecast of ($0.01). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.07) per share. HC Wainwright also issued estimates for Lineage Cell Therapeutics’ Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.08) EPS and FY2027 earnings at ($0.09) EPS.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03). The firm had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $1.84 million. Lineage Cell Therapeutics had a negative return on equity of 82.83% and a negative net margin of 246.58%.

Several other research analysts have also issued reports on LCTX. D. Boral Capital reissued a “buy” rating and set a $3.00 target price on shares of Lineage Cell Therapeutics in a research note on Monday, May 4th. Canaccord Genuity Group began coverage on shares of Lineage Cell Therapeutics in a research note on Tuesday, April 28th. They issued a “buy” rating and a $9.00 price target for the company. Four analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $6.25.

Lineage Cell Therapeutics Stock Up 2.7%

NYSEAMERICAN:LCTX opened at $1.13 on Tuesday. The company has a fifty day moving average of $1.20 and a 200-day moving average of $1.44. The firm has a market capitalization of $285.79 million, a P/E ratio of -5.95 and a beta of 1.53. Lineage Cell Therapeutics has a twelve month low of $0.97 and a twelve month high of $2.09.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Fifth Third Bancorp bought a new stake in Lineage Cell Therapeutics during the 1st quarter worth approximately $7,268,000. Ascentis Independent Advisors bought a new position in shares of Lineage Cell Therapeutics in the first quarter valued at approximately $49,000. Nwam LLC lifted its holdings in shares of Lineage Cell Therapeutics by 77.5% in the fourth quarter. Nwam LLC now owns 62,131 shares of the company’s stock valued at $99,000 after purchasing an additional 27,131 shares in the last quarter. Red Crane Wealth Management LLC boosted its position in shares of Lineage Cell Therapeutics by 16.8% during the fourth quarter. Red Crane Wealth Management LLC now owns 597,263 shares of the company’s stock valued at $997,000 after buying an additional 85,900 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of Lineage Cell Therapeutics during the fourth quarter valued at approximately $25,000. 62.47% of the stock is owned by institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.